Citations

Showing 10 of 108104 citations.

A Simplified Approach to Adnexal Lesions May Be Enough
Baumgarten, Deborah A.

Mayo Clinic

Radiology | March 22, 2022 | Volume: 303 | Issue: 3 | Pages: 611-612

10.1148/radiol.220199 | PMID 35315724 Get It

Strategies to Account for Design Misspecifications in Randomized Controlled Trials
Ruppert, Amy S. , Mandrekar, Sumithra J.

Mayo Clinic

NEJM Evidence | March 22, 2022 | Volume: 1 | Issue: 4 | Pages: No page available

10.1056/evide2200012 | PMID 38319209 Get It

Predicting Neuroworsening in Moderate Traumatic Brain Injury: Less Is More?
Godoy, Daniel Agustín , Rabinstein, Alejandro A.

Mayo Clinic

Journal of Neurotrauma | March 22, 2022 | Volume: 39 | Issue: 11-12 | Pages: 891-892

10.1089/neu.2022.0124 | PMID 35316075 Get It

Carbon ion radiotherapy in the management of non‐small cell lung cancer
Seneviratne, Danushka S. , Mao, Jingfang, Dougherty, Jingjing M. , Bush, Aaron , Thomas, Mathew , Lou, Yanyan , Owen, Dawn , Kirwan, Jessica, Thomas, Mathew , Thomas, Mathew , Ishikawa, Hitoshi , Manochakian, Rami , Sio, Terence T. , Ko, Stephen J. , Hoppe, Bradford S.

Mayo Clinic

Precision Radiation Oncology | March 22, 2022 | Volume: 6 | Issue: 1 | Pages: 69-74

10.1002/pro6.1146 Get It

AbstractDespite advancements in local‐regional and systemic therapies, non‐small cell cancer (NSCLC) remains a leading cause of death worldwide. Among those treated with standard‐of‐care modalities, 30–60% experience disease recurrence. Carbon ion radiotherapy (CIRT) is a form of densely ionizing radiotherapy with unique physical and biological advantages over traditional photon and proton modalities. CIRT is expected to have a superior biological impact on tumors, and is believed to be less impacted by the presence of tumor hypoxia or cell cycle state. It also shows highly conformal physical dose deposition due to reduced lateral scattering of the particles, limiting the radiation dose delivered to adjacent organs at risk. To implement CIRT as a viable option in the treatment of NSCLC, technical aspects of treatment delivery – including appropriate beam arrangements, dose calculation algorithms, radiobiological models, and methods of motion management – must be thoroughly investigated. Furthermore, randomized clinical trials comparing CIRT versus traditional radiation modalities must be performed to show the benefits and risks associated with this novel treatment modality. This review discusses the rationale for utilizing CIRT in NSCLC, available clinical data to date, and the potential for future investigations that may pave the path for improving outcomes in those diagnosed with NSCLC.
Is there more than meets the eye? Spontaneous coronary artery dissection and sudden cardiac death
Giudicessi, John R. , Hayes, Sharonne N. , Hayes, Sharonne N

Mayo Clinic

Cardiovascular Research | March 22, 2022 | Volume: 118 | Issue: 7 | Pages: 1615-1617

10.1093/cvr/cvac043 | PMID 35425981 Get It

Product characteristics should be reported in all biological therapy publications
Buchheit, Thomas Edward , Hunt, Christine , Eldrige, Jason S. , Eshraghi, Yashar , Souza, Dmitri , Buchheit, Thomas , Eldrige, Jason, Hunt, Christine

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 22, 2022 | Volume: 47 | Issue: 7 | Pages: 449.1-449

10.1136/rapm-2022-103557 | PMID 35318261 Get It

Response to Bellini et al.
Wald, Arnold , Bharucha, Adil E. , Malcolm, Allison , Malcolm, Allison , Remes Troche, José M

Mayo Clinic

American Journal of Gastroenterology | March 22, 2022 | Volume: 117 | Issue: 5 | Pages: 809-810

10.14309/ajg.0000000000001677 | PMID 35315800 Get It

A suppressor of dioxygenase inhibition in a yeast model of SDH deficiency
Beimers, William , Braun, Megan, Schwinefus, Kaleb, Pearson, Keenan, Wilbanks, Brandon, Maher, L. James , Wilbanks, Brandon , Pearson, Keenan , III, Louis James Maher , Pearson, Keenan S , Wilbanks, Brandon A , Beimers, William , Braun, Megan, Schwinefus, Kaleb, Pearson, Keenan

Mayo Clinic

Endocrine-Related Cancer | March 22, 2022 | Volume: 29 | Issue: 6 | Pages: 345-358

10.1530/erc-21-0349 | PMID 35315791 Get It

A fascinating class of familial paraganglioma (PGL) neuroendocrine tumors is driven by the loss of the tricarboxylic acid (TCA) cycle enzyme succinate dehydrogenase (SDH) resulting in succinate accumulation as an oncometabolite and other metabolic derangements. Here, we exploit a Saccharomyces cerevisiae yeast model of SDH loss where accumulating succinate, and possibly reactive oxygen species, poison a dioxygenase enzyme required for sulfur scavenging. Using this model, we performed a chemical suppression screen for compounds that relieve dioxygenase inhibition. After testing 1280 pharmaceutically active compounds, we identified meclofenoxate HCl and its hydrolysis product, dimethylaminoethanol (DMAE), as suppressors of dioxygenase intoxication in SDH-loss yeast cells. We show that DMAE acts to alter metabolism so as to normalize the succinate:2-ketoglutarate ratio, improving dioxygenase function. This study raises the possibility that oncometabolite effects might be therapeutically suppressed by drugs that rewire metabolism to reduce the flux of carbon into pathological metabolic pathways.
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient‐level data from 4 prospective trials
Perlow, Haley K. , Prasad, Rahul N. , Yang, Mike, Klamer, Brett , Matsui, Jennifer K. , Scorsetti, Marta , Clerici, Elena , Arnett, Andrea , Beyer, Sasha , Ammirati, Mario , Chakravarti, Arnab , Raval, Raju R. , Brown, Paul D. , Navarria, Pierina , Scoccianti, Silvia , Grecula, J.C., Chakravarti, Arnab , Brown, Paul D , Palmer, Joshua D , Perlow, Haley K , Chakravarti, Arnab , Scorsetti, Marta , Marrazzo, L. , Detti, Beatrice , Palmer, Joshua D.

Mayo Clinic

Cancer | March 22, 2022 | Volume: 128 | Issue: 12 | Pages: 2367-2374

10.1002/cncr.34192 | PMID 35315512 Get It

BackgroundThe standard of care for elderly or frail patients with glioblastoma (GBM) is 40 Gy in 15 fractions of radiotherapy. However, this regimen has a lower biological effective dose (BED) compared with the Stupp regimen of 60 Gy in 30 fractions. It is hypothesized that accelerated hypofractionated radiation of 52.5 Gy in 15 fractions (BED equivalent to Stupp) is safe and efficacious.MethodsElderly or frail patients with GBM treated with 52.5 Gy in 15 fractions were pooled from 3 phase 1/2 studies and a prospective observational study. Overall survival (OS) and progression‐free survival (PFS) were defined time elapsing between surgery/biopsy and death from any cause or progression of disease.ResultsSixty‐two newly diagnosed patients were eligible for this pooled analysis of individual patient data. The majority (66%) had a Karnofsky performance status (KPS) score <70. The median age was 73 years. The median OS and PFS were 10.3 and 6.9 months, respectively. Patients with KPS scores ≥70 and <70 had a median OS of 15.3 and 9.5 months, respectively. Concurrent chemotherapy was an independent prognostic factor for improved PFS and OS. Grade 3 neurologic toxicity was seen in 2 patients (3.2%). There was no grade 4/5 toxicity.ConclusionsThis is the only analysis of elderly/frail patients with GBM prospectively treated with a hypofractionated radiation regimen that is isoeffective to the Stupp regimen. Treatment was well tolerated and demonstrated excellent OS and PFS compared with historical studies. This regimen gives the elderly/frail population an alternative to regimens with a lower BED. Randomized trials are needed to validate these results.
Colorectal cancer screening preferences among physicians and individuals at average risk: A discrete choice experiment
Heidenreich, Sebastian , Rutten, Lila J. Finney , Miller‐Wilson, Lesley‐Ann , Jimenez‐Moreno, Cecilia , Chua, Gin Nie , Fisher, Deborah A. , Finney Rutten, Lila J

Mayo Clinic

Cancer Medicine | March 22, 2022 | Volume: 11 | Issue: 16 | Pages: 3156-3167

10.1002/cam4.4678 | PMID 35315224 Get It

AbstractBackgroundGuidelines include several options for average‐risk colorectal cancer (CRC) screening that vary in aspects such as invasiveness, recommended frequency, and precision. Thus, patient and provider preferences can help identify an appropriate screening strategy. This study elicited CRC screening preferences of physicians and individuals at average risk for CRC (IAR).MethodsIAR aged 45–75 years and licensed physicians (primary care or gastroenterology) completed an online discrete choice experiment (DCE). Participants were recruited from representative access panels in the US. Within the DCE, participants traded off preferences between screening type, screening frequency, true‐positive, true‐negative, and adenoma true positive (physicians only). A mixed logit model was used to obtain predicted choice probabilities for colonoscopy, multi‐target stool DNA (mt‐sDNA), fecal immunochemical test (FIT), and methylated septin 9 (mSEPT9) blood test.ResultsPreferences of IAR and physicians were affected by screening precision and screening type. IAR also valued more regular screening. Physicians preferred colonoscopy (96.8%) over mt‐sDNA (2.8%; p < 0.001), FIT (0.3%; p < 0.001) and mSEPT9 blood test (0.1%; p < 0.01). IAR preferred mt‐sDNA (38.8%) over colonoscopy (32.5%; p < 0.001), FIT (19.2%; p < 0.001), and mSEPT9 blood test (9.4%; p < 0.001). IAR naïve to screening preferred non‐invasive screening (p < 0.001), while the opposite was found for those who previously underwent colonoscopy or sigmoidoscopy.ConclusionsWhile physicians overwhelmingly preferred colonoscopy, preferences of IAR were heterogenous, with mt‐sDNA being most frequently preferred on average. Offering choices in addition to colonoscopy could improve CRC screening uptake among IAR.This study used a discrete choice experiment in the US to elicit preferences of physicians and individuals at average risk for colorectal cancer screening modalities and their characteristics.